AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Besse, Benjamin
Felip, Enriqueta
Clifford, Corinne
Louie-Gao, Melinda
Green, Jennifer
Turner, Christopher D.
Popat, Sanjay
机构：
[1] Gustave Roussy Univ Paris Sud, Villejuif, France
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Blueprint Med Inc, Cambridge, MA USA
[4] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9633
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC
    Besse, B.
    Felip, E.
    Kim, E. S.
    Clifford, C.
    Louie-Gao, M.
    Yagui-Beltran, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S44 - S45
  • [2] AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC
    Besse, B.
    Felip, E.
    Kim, E. S.
    Clifford, C.
    Louie-Gao, M.
    Yagui-Beltran, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S684 - S684
  • [3] AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion-positive advanced/metastatic NSCLC.
    Popat, Sanjay
    Felip, Enriqueta
    Kim, Edward S.
    de Marinis, Filippo
    Cho, Byoung Chul
    Wermke, Martin
    De langen, Adrianus
    Ferrara, Roberto
    Kanzler, Stephan
    Cecere, Fabiana Letizia
    Galetta, Domenico
    Lee, Dae Ho
    Gregorc, Vanesa
    Rodrigues, Ana
    Britschgi, Christian
    Rahman, Ahmadur
    Ndunda, Diana
    Noe, Johannes
    Lu, Danny
    Besse, Benjamin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC)
    Besse, B.
    Griesinger, F.
    Curigliano, G.
    Thomas, M.
    Subbiah, V.
    Baik, C. S.
    Tan, D. S. W.
    Lee, D. H.
    Garralda, E.
    Kim, D-W.
    Van Der Wekken, A. J.
    Gainor, J.
    Paz-Ares, L.
    Liu, S. V.
    Bowles, D. W.
    Zalutskaya, A.
    Ruf, T.
    Rahman, A.
    Chen, G.
    Mazieres, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1083 - S1084
  • [5] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer
    Zhou, Q.
    Wu, Y.
    Chang, J.
    Wang, H.
    Fan, Y.
    Zhao, J.
    Wu, G.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Nian, W.
    Wang, K.
    Zheng, X.
    Qu, L.
    Yao, S.
    Shen, Z.
    Li, P.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S889 - S890
  • [6] Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion plus non-small cell lung cancer
    Zhou, Q.
    Wu, Y-L.
    Zhao, J.
    Chang, J.
    Wang, H.
    Fan, Y.
    Wang, K.
    Wu, G.
    Nian, W.
    Gong, Y.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Zheng, X.
    Qin, M.
    Duan, X.
    Shen, Z.
    Yao, S.
    Yang, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1593 - S1593
  • [7] Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Lee, Dae Ho
    Curigliano, Giuseppe
    Doebele, Robert Charles
    Kim, Dong-Wan
    Baik, Christina S.
    Tan, Daniel Shao-Weng
    Lopes, Gilberto
    Gadgeel, Shirish M.
    Cassier, Philippe Alexandre
    Taylor, Matthew H.
    Liu, Stephen V.
    Besse, Benjamin
    Thomas, Michael
    Zhu, Viola Weijia
    Zhang, Hui
    Clifford, Corinne
    Palmer, Michael
    Turner, Christopher D.
    Subbiah, Vivek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [9] Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe Alexandre
    Lopes, Gilberto
    Tan, Daniel Shao-Weng
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen, V
    Clifford, Corinne
    Zhang, Hui
    Turner, Christopher D.
    Subbiah, Vivek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Drilon, A.
    Subbiah, V.
    Gautschi, O.
    Tomasini, P.
    De Braud, F. G. M.
    Solomon, B.
    Tan, D. Shao-Weng
    Alonso, G.
    Wolf, J.
    Park, K.
    Goto, K.
    Soldatenkova, V.
    Szymczak, S.
    Barker, S.
    Puri, T.
    Lin, A. B.
    Loong, H. H. F.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S43 - S43
12345